---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-031269"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:51:46.696694+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lyell Q1 net loss narrows to $24.2M; ronde-cel PiNACLE on track for pivotal data mid-2027

## Summary
- Net loss $24.2M vs $52.2M a year ago; non-GAAP net loss $37.8M vs $46.3M.
- Cash $261M as of March 31, 2026, providing runway into Q3 2027.
- PiNACLE trial for ronde-cel in 3L+ LBCL: additional data H2 2026, pivotal data mid-2027, BLA submission 2027 expected.
- Phase 3 PiNACLE-H2H (ronde-cel vs standard CAR T) commenced dosing; LYL273 Phase 1 for mCRC at Dose Level 3.
- Closed second $50M tranche of private placement at $25.61/share; total $100M; Smital Shah appointed CFO.

## SEC filing metadata
- accession: 0001628280-26-031269
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828026031269/0001628280-26-031269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828026031269/lyel-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-031269
- JSON: https://secwatch.observer/filing/0001628280-26-031269.json
- Plain text: https://secwatch.observer/filing/0001628280-26-031269.txt

## Key facts
- Earnings Releases
  Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2026 results: net income net loss of $24.2 million.
  - Period: the first quarter ended March 31, 2026
  - Net income: net loss of $24.2 million
  - Result: reported results
  source text: Lyell reported a net loss of $24.2 million for the first quarter ended March 31, 2026, compared to a net loss of $52.2 million for the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000162828026031269/0001628280-26-031269-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.